New precision trial aims to intercept AML relapse before it starts
NCT ID NCT06664879
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 21 times
Summary
This study tests whether giving personalized, targeted drugs to people with acute myeloid leukemia (AML) can prevent the cancer from returning early. It is for patients who show signs of remaining cancer cells after initial treatment. The approach uses genetic testing to match each person with the most promising therapy, aiming to control the disease and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.